Transforming Immunotherapy for Hematologic Disorders
Latest News
Cimeio Therapeutics Therapy Platform Featured in Forbes Article
Cimeio Therapeutics Therapy Platform Featured in Forbes Article Basel, Switzerland, and Cambridge, MA, August 20, 2024 Cimeio Therapeutics is thrilled to announce that our therapy platform has been featured in a recent Forbes article, highlighting our groundbreaking...
Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers
Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers -- Selective and complete eradication of leukemic cells with an ADC targeting the pan-blood marker CD45 -- --...
Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT
Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT -- Cimeio’s CD52 shielding variant protects cells from depletion by Alemtuzumab while maintaining processing, cell surface expression and function -- -- Program serves as the basis for a novel...
Latest Publications
Selective haematological cancer eradication with preserved haematopoiesis
Simon Garaudé1,2,15,Romina Marone1,2,15, Rosalba Lepore1,2,3, Anna Devaux1,2, Astrid Beerlage1,2,4, Denis Seyres1,2, Alessandro Dell’ Aglio1,2, Darius Juskevicius5, Jessica Zuin1,2, Thomas Burgold1,2, Sisi Wang6, Varun Katta7, Garret Manquen7, Yichao Li7, Clément...
Molecular shielding of CD52 retains expression, anti-phagocytic ‘don’t eat me’ function and protects from Alemtuzumab-mediated depletion
Anna Camus1*, Emiel ten Buren1*, Laura Garcia-Prat1, Julie Brault1, Valentin Do Sacramento1, Sophie Lackner1, Rosalba Lepore1,2, Benedetta Romeo1, Mathilde Testut1, Daniel Klin1, Izabela Durzynska3, Saniye Yumlu1, & Stefanie Urlinger11Cimeio Therapeutics AG, Basel,...
Base-Edited HSPCs Are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression
Astrid Beerlage, MD1,2, Simon Garaudé1,2, Rosalba Lepore, PhD1,2,3, Thomas Burgold, PhD1,2,3, Anna Camus, PhD3, Mathilde Testut3, Stefanie Urlinger, PhD3 and Lukas T Jeker, MD PhD1,2,31Department of Biomedicine, University of Basel, Basel, Switzerland 2Transplantation...
Treatment
Shielded Cell & Immunotherapy Pairs™
Our proprietary immunotherapies deplete diseased cells, while our cell-shielding technology protects healthy cells.
Because the healthy cells are protected, the immunotherapy can be safely administered to boost engraftment or treat minimal residual disease.
Technology
Cell Shielding
We use gene editing tools to insert novel protein variants into HSCs or other types of cells, allowing the cells to maintain their function while making them resistant to depletion by the paired immunotherapy.
Our shielding technology has proven to be effective in shielding cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells.
